Phase 3 Trial Success: Recent discussions on X about Belite Bio (BLTE) have been ignited by the company’s announcement of positive topline results from its Phase 3 DRAGON trial for Tinlarebant. Many users are excited about the drug’s potential to treat Stargardt Disease, a condition previously deemed untreatable. The stock saw a notable pre-market surge following the news, as shared across multiple posts.
Analyst Optimism: Adding to the buzz, a major analyst firm recently maintained a 'Buy' rating for BLTE and raised its price target significantly to $185. This has fueled further conversation on X, with some users echoing the optimism about future growth. However, a few remain cautious due to a recent public offering announcement that led to a slight after-hours dip.
Note: This discussion summary was generated from an AI condensation of post data.
Belite Bio Hedge Fund Activity
We have seen 27 institutional investors add shares of Belite Bio stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 875,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $64,750,000
- VESTAL POINT CAPITAL, LP added 312,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $23,125,000
- SOLEUS CAPITAL MANAGEMENT, L.P. added 210,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $15,540,000
- EVENTIDE ASSET MANAGEMENT, LLC added 195,312 shares (+inf%) to their portfolio in Q3 2025, for an estimated $14,453,088
- MARSHALL WACE, LLP added 178,014 shares (+1876.6%) to their portfolio in Q3 2025, for an estimated $13,173,036
- ALYESKA INVESTMENT GROUP, L.P. removed 83,623 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,825,047
- PERCEPTIVE ADVISORS LLC added 49,788 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,684,312
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Belite Bio Analyst Ratings
Wall Street analysts have issued reports on $BLTE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/01/2025
- Cantor Fitzgerald issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for Belite Bio, check out Quiver Quantitative's $BLTE forecast page.
Belite Bio Price Targets
Multiple analysts have issued price targets for $BLTE recently. We have seen 4 analysts offer price targets for $BLTE in the last 6 months, with a median target of $143.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $185.0 on 12/01/2025
- Steve Seedhouse from Cantor Fitzgerald set a target price of $154.0 on 11/24/2025
- Graig Suvannavejh from Mizuho set a target price of $105.0 on 11/20/2025
- Bruce D. Jackson from Benchmark set a target price of $132.0 on 10/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
